Trends In Therapeutic Partnering
The Trends in Therapeutic Partnering report provides the most comprehensive and in-depth insight into the 35 most popular therapeutic targets for partnering in the period 2007 to mid 2013.
To Read The Complete Report with TOC:-
The report provides a detailed understanding and analysis of the most popular therapeutic targets for partnering in the period 2007 to mid 2013. The majority of deals are discovery, preclinical and clinical stage whereby the licensee obtains a right or an option right to license or access the licensors compounds or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapeutic targets. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.
Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. Over 300 charts allow quick understanding of therapeutic partnering trends since 2007, together with insight into which companies are active in each of the thirty five leading therapeutic areas.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
To Buy a Copy Of This Report:-
The initial chapters of this report provide an orientation of therapeutic dealmaking.
Chapter 1 provides an introduction to the report, whilst
Chapter 2 provides an overview of therapeutic dealmaking since 2007, listing the top therapeutic areas for partnering by deal frequency and deal dollars committed by partnering companies.
Chapter 3 reviews the top pharma and biotech therapeutic partnering deals of 2007-2013 according to reported deal size.
Chapter 4 provides a summary on best practice on how to submit an opportunity to the leading therapeutic partnering companies, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.
Chapter 5 lists forthcoming partnering events where valuable face to face meetings with big biotech provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948